Patents by Inventor Owe Orwar

Owe Orwar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210038577
    Abstract: The present invention provides inhibitors of thioredoxin reductase, in particular selenium compromised thioredoxin reductase-derived apoptotic protein (SecTRAP) forming agents, for use in treating an immune cell infiltrated cancer (e.g. a T-cell infiltrated cancer) in a subject, wherein said agents stimulate an anti-cancer immune response. The present invention also provides combinations comprising a SecTRAP forming agent and other therapeutic agents for use in treating cancer.
    Type: Application
    Filed: February 12, 2019
    Publication date: February 11, 2021
    Inventors: Owe Orwar, Max Davidson
  • Publication number: 20200165554
    Abstract: One aspect of the invention provides a system for dispensing and printing cells and particles. The system includes: (a) a flow confinement device; (b) a controller configured to generate a confined liquid volume outside the flow confinement device, wherein the confined liquid volume or materials contained in the confined liquid volume can be released to the environment by confined, modulated, and non-confined flow modes in arbitrary sequence and for arbitrary periods of time by said controller; (c) one or more liquids containing cells or cell constituents supplied into the confined liquid volume through the flow confinement device; (d) a substrate; and (e) a system configured to position the flow confinement device in 3D space and, therefore, the confined liquid volume to be positioned relative to the substrate, such that the confined liquid volume and contents, can interact with the substrate.
    Type: Application
    Filed: January 28, 2020
    Publication date: May 28, 2020
    Inventors: Owe Orwar, Alar Ainla, Gavin David Michael Jeffries, Shijun Xu
  • Publication number: 20200138782
    Abstract: The present invention relates to a pharmaceutical combination comprising a CDK inhibitor and at least one antioxidant enzyme inhibitor for use in the treatment of cancer. The present invention also relates to a method for the treatment of cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one antioxidant enzyme inhibitor. The pharmaceutical combination of the present invention exhibits synergistic effect when used in the treatment of cancer.
    Type: Application
    Filed: December 23, 2019
    Publication date: May 7, 2020
    Applicant: Piramal Enterprises Limited
    Inventors: Owe ORWAR, Sreesha SRINIVASA, Prabha MISHRA
  • Patent number: 10555931
    Abstract: The present invention relates to a pharmaceutical combination comprising a CDK inhibitor and at least one antioxidant enzyme inhibitor for use in the treatment of cancer. The present invention also relates to a method for the treatment of cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one antioxidant enzyme inhibitor. The pharmaceutical combination of the present invention exhibits synergistic effect when used in the treatment of cancer.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: February 11, 2020
    Assignee: PIRAMAL ENTERPRISES LIMITED
    Inventors: Owe Orwar, Sreesha Srinivasa, Prabha Mishra
  • Publication number: 20200041499
    Abstract: The present invention relates to methods of identifying an epitope on a protein that can be bound by an antibody. Methods of the invention typically involve a step of limited or restricted proteolysis of a protein using a single first protease or a combination of first proteases, and a further proteolysis step using a single second protease or combination of second proteases. The invention also relates to identified epitopes and to antibodies which bind to epitopes that have been identified by methods of the invention.
    Type: Application
    Filed: October 6, 2017
    Publication date: February 6, 2020
    Applicant: OBLIQUE THERAPEUTICS AB
    Inventors: Owe ORWAR, Carolina TRKULJA, Max DAVIDSON, Jessica HÄGGLUND
  • Publication number: 20200024233
    Abstract: There is provided compounds of formula I (I) or pharmaceutically-acceptable salts thereof, wherein L, R1, R2, R3, R4 and n have meanings provided in the description, which compounds are useful in the treatment of cancers.
    Type: Application
    Filed: February 7, 2018
    Publication date: January 23, 2020
    Inventors: Benjamin Pelcman, Owe Orwar, William Stafford, Kjell Andersson
  • Publication number: 20190194320
    Abstract: The present invention relates to methods of identifying an epitope on a protein that can be bound by an antibody. Methods of the invention typically involve a step of limited or restricted proteolysis of a protein and the identification of sites on the protein that are cut by the protease(s) used. The invention also relates to antibodies which bind to epitopes that have been identified by methods of the invention.
    Type: Application
    Filed: September 1, 2017
    Publication date: June 27, 2019
    Applicant: OBLIQUE THERAPEUTICS AB
    Inventors: Owe ORWAR, Carolina TRKULJA, Max DAVIDSON
  • Publication number: 20180111990
    Abstract: The present invention relates to certain new methods to select epitopes for antibodies. The present invention also provides a method of generating an antibody (e.g. a functional antibody) to a protein, said method comprising (i) identifying an antigenic epitope in said protein by exposing the protein to limited or restricted proteolysis by contacting the protein with at least one protease to form at least one digested, deconstructed or truncated version of the protein and at least one surface-exposed peptide that is cleaved off from the protein by the action of said protease and generating an antigenic epitope based on said surface-exposed peptide; and (ii) raising an antibody against the antigenic epitope. The present invention also provides antigenic epitopes and antibodies against such epitopes.
    Type: Application
    Filed: March 31, 2016
    Publication date: April 26, 2018
    Applicant: OBLIQUE THERAPEUTICS AB
    Inventors: Owe ORWAR, Carolina TRKULJA
  • Patent number: 9671366
    Abstract: One embodiment of the invention provides a system adapted and configured to generate a localized flow circulation zone. The system includes: a free-standing microfluidic pipette comprising three or more channels with exits separated from each other by an outer surface of the pipette; and a controller programmed to control fluid flows through each of the three or more channels to generate a localized recirculating fluid flow path outside the pipette. Liquid leaving the microfluidic pipette through at least one outlet channel exit is withdrawn through at least two inlet channel exits.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: June 6, 2017
    Assignee: Fluicell AB
    Inventors: Owe Orwar, Alar Ainla, Aldo Jesorka
  • Patent number: 9658240
    Abstract: Aspects of the present invention provide a freestanding microfluidic pipette with integrated wells for solution storage. Further aspects of the invention provide a holding interface to provide connectivity with external control components. One aspect of the invention provides a system for applying a microfluidic device in microscopy. The system includes: a microfluidic device having an elongated shape and defining one or more wells for solution storage and processing; and an interface adapted and configured to hold the microfluidic device in a freestanding manner and facilitate simultaneous connection of the one or more wells with a flow controller. Another aspect of the invention provides a method for utilizing a microfluidic device. The method includes: providing a device as described herein; positioning the device adjacent to a microscope; and actuating the interface to operate the microfluidic device.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: May 23, 2017
    Assignee: Fluicell AB
    Inventors: Owe Orwar, Alar Ainla, Aldo Jesorka, Gavin Jeffries
  • Publication number: 20170112809
    Abstract: The present invention relates to a pharmaceutical combination comprising a CDK inhibitor and at least one antioxidant enzyme inhibitor for use in the treatment of cancer. The present invention also relates to a method for the treatment of cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one antioxidant enzyme inhibitor. The pharmaceutical combination of the present invention exhibits synergistic effect when used in the treatment of cancer.
    Type: Application
    Filed: May 27, 2015
    Publication date: April 27, 2017
    Applicant: Piramal Enterprises Limited
    Inventors: Owe ORWAR, Sreesha SRINIVASA, Prabha MISHRA
  • Publication number: 20150346147
    Abstract: One embodiment of the invention provides a system adapted and configured to generate a localized flow circulation zone. The system includes: a free-standing microfluidic pipette comprising three or more channels with exits separated from each other by an outer surface of the pipette; and a controller programmed to control fluid flows through each of the three or more channels to generate a localized recirculating fluid flow path outside the pipette. Liquid leaving the microfluidic pipette through at least one outlet channel exit is withdrawn through at least two inlet channel exits.
    Type: Application
    Filed: August 11, 2015
    Publication date: December 3, 2015
    Applicant: FLUICELL AB
    Inventors: Owe Orwar, Alar Ainla, Aldo Jesorka
  • Patent number: 9126197
    Abstract: The present invention features a freestanding microfluidic pipette with both solution exchange capability and fluid re-circulation, enabling highly localized and contamination- free fluid delivery within a confined volume in the vicinity of the pipette exit. Preferably, the device features direct positioning, so the pipette can be directed at a point or object of interest, such as a biological or artificial cell, a defined surface area or a sensor element within an open volume, using micro- or nanopositioning techniques. One aspect of the invention provides a free-standing pipette. The free-standing pipette includes a microfluidic device comprising one or more channels with exits leading into an open-volume and a positioning device programmed to hold the microfluidic device at an angle from a horizontal axis.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: September 8, 2015
    Assignee: Fluicell AB
    Inventors: Owe Orwar, Alar Ainla, Aldo Jesorka
  • Publication number: 20140147930
    Abstract: Aspects of the present invention provide a freestanding microfluidic pipette with integrated wells for solution storage. Further aspects of the invention provide a holding interface to provide connectivity with external control components. One aspect of the invention provides a system for applying a microfluidic device in microscopy. The system includes: a microfluidic device having an elongated shape and defining one or more wells for solution storage and processing; and an interface adapted and configured to hold the microfluidic device in a freestanding manner and facilitate simultaneous connection of the one or more wells with a flow controller. Another aspect of the invention provides a method for utilizing a microfluidic device. The method includes: providing a device as described herein; positioning the device adjacent to a microscope; and actuating the interface to operate the microfluidic device.
    Type: Application
    Filed: November 5, 2013
    Publication date: May 29, 2014
    Applicant: Avalance Biotech AB
    Inventors: Owe Orwar, Alar Ainla, Aldo Jesorka, Gavin Jeffries
  • Patent number: 8426205
    Abstract: Disclosed is a method for selective electrofusion of at least two fusion partners having cell-like membranes and cellular or subcellular dimensions, comprising the following steps: A) the fusion partners are brought into contact with each other and B) an electrical field of a strength sufficient to obtain fusion and highly focused on the fusion partners is applied. The fusion partners are independently selected from the group consisting of a single cell, a liposome, a proteoliposome, a synthetic vesicle, an egg cell, an enucleated egg cell, a sperm cell at any development stage and a plant protoplast.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: April 23, 2013
    Assignee: Collectricon AB
    Inventors: Peter Eriksson, Daniel T. Chiu, Alexander Moscho, Owe Orwar, Richard N. Zare
  • Publication number: 20130052737
    Abstract: Disclosed is a method for selective electrofusion of at least two fusion partners having cell-like membranes and cellular or subcellular dimensions, comprising the following steps: A) the fusion partners are brought into contact with each other and B) an electrical field of a strength sufficient to obtain fusion and highly focused on the fusion partners is applied. The fusion partners are independently selected from the group consisting of a single cell, a liposome, a proteoliposome, a synthetic vesicle, an egg cell, an enucleated egg cell, a sperm cell at any development stage and a plant protoplast.
    Type: Application
    Filed: July 23, 2012
    Publication date: February 28, 2013
    Applicant: CELLECTRICON AB
    Inventors: Peter Eriksson, Daniel T. Chiu, Alexander Moscho, Owe Orwar, Richard N. Zare
  • Publication number: 20130017553
    Abstract: The present invention features a freestanding microfluidic pipette with both solution exchange capability and fluid re-circulation, enabling highly localized and contamination- free fluid delivery within a confined volume in the vicinity of the pipette exit. Preferably, the device features direct positioning, so the pipette can be directed at a point or object of interest, such as a biological or artificial cell, a defined surface area or a sensor element within an open volume, using micro- or nanopositioning techniques. One aspect of the invention provides a free-standing pipette. The free-standing pipette includes a microfluidic device comprising one or more channels with exits leading into an open-volume and a positioning device programmed to hold the microfluidic device at an angle from a horizontal axis.
    Type: Application
    Filed: June 1, 2012
    Publication date: January 17, 2013
    Inventors: Owe Orwar, Alar Ainla, Aldo Jesorka
  • Patent number: 8338150
    Abstract: Disclosed is a method for parallel delivery of agents to and/or into a cell structure, wherein at least two electrolyte-filled tubes are provided together with a counter electrode, the tubes being connected to a voltage or current generator, said agents being introduced into the electrolyte solution contained in the tubes, which are placed close to the cell structure, whereupon the agents are transported through the tubes to said cell structure and into the said structure through pores which have been formed by application of an electric field focused on the cell structure, resulting in electroporation of the cell structure. Also different applications of the method is disclosed, e.g. use of the method in order to transfer cell-impermeant solutes, such as drugs or genes, into the cell structure or out of the cell structure.
    Type: Grant
    Filed: June 9, 2008
    Date of Patent: December 25, 2012
    Assignee: Cellectricon AB
    Inventors: Owe Orwar, Mattias Karlsson, Kerstein Nolkrantz, Cecilia Farre
  • Patent number: 8268555
    Abstract: Disclosed is a method for sequential delivery of agents to and/or into a cell structure, wherein an electrolyte-filled tube is provided together with a counter electrode, said tube is connected to a voltage or current generator, at least two agents are introduced in a discrete mode into the electrolyte solution contained in the tube, which is placed close to the cell structure, one agent at the time being transported through the tube to and/or into said cell structure in which a pore has been formed by application of an electric field focused on the cell structure, resulting in electroporation of the cell structure. Also different applications of the method is disclosed, e.g. us of the method in order to transfer cell-impermeant solutes, such as drugs or genes, into the cell structure or out of the cell structure.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: September 18, 2012
    Assignee: Cellectricon AB
    Inventors: Owe Orwar, Mattias Karlsson, Cecilia Farre, Kerstin Nolkrantz
  • Patent number: 8232074
    Abstract: The present invention relates to methods of measuring electrical properties of a cell using electrode devices comprising tapered nanotips having submicrometer dimensions (“nanoelectrodes”) for insertion into a cell. The devices are used to measure electrical properties of the cell and, optionally, may be used to electroporate, the cell or subcellular structures within the cell. The invention also provides arrays of electrode devices having nanotips for simultaneously or sequentially measuring the electrical properties of cells (e.g., such as surface immobilized cells). The electrodes can be used to measure properties of ion channels and in HTS assays to identify drugs which affect the properties of ion channels. The invention additionally provides microfluidic systems adapted for use with the electrode devices having nanotips. In combination with the electrodes, the microfluidic systems provide cell-based biosensors for monitoring cellular responses to conditions, such as exposure to candidate drugs.
    Type: Grant
    Filed: October 15, 2003
    Date of Patent: July 31, 2012
    Assignee: Cellectricon AB
    Inventors: Kent Jardemark, Aldo Jesorka, Mattias Karlsson, Jessica Olofsson, Owe Orwar, Johan Pihl, Eskil Sahlin